Mark Cuban Comments on FTC Settlement with Express Scripts Amid 340B Program’s Role in Hospital Consolidations

The latest developments in the pharmaceutical and healthcare sectors highlight several key issues shaping the industry. Recent updates include Mark Cuban’s commentary on the Federal Trade Commission (FTC) settlement with Express Scripts, insights into patient preferences for health insurance, an analysis of how Quality-Adjusted Life Years (QALYs) could impact the Most Favored Nation (MFN) pricing model, and a look at how the 340B Drug Pricing Program is influencing hospital vertical integration. Additionally, new team members have joined the Drug Channels Institute.

Mark Cuban weighed in on the FTC’s settlement with Express Scripts, offering his perspective on its implications for pharmacy benefit managers and drug pricing transparency. Meanwhile, a report examined what patients prioritize when it comes to health insurance coverage, shedding light on consumer expectations in healthcare plans. Another analysis explored how QALY metrics might create challenges for implementing MFN pricing policies aimed at reducing drug costs. The 340B program also came under scrutiny for its role in driving hospital acquisitions and consolidations by shifting care sites to maximize financial benefits. Lastly, the Drug Channels Institute announced an expansion of its team as it continues to monitor trends across the pharmaceutical landscape.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 24, 2026

Author

GOAI